Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719755 | 0.81 | MAPK8 (0.48) | PARP1 | |
| SCHEMBL1720314 | 0.81 | PARP1 (0.46) | PARP1KDM4E | |
| SCHEMBL11278033 | 0.80 | PARP1 (0.56) | PARP1HPGDCYP1A2CYP2C9KDM4E | |
| SCHEMBL11286643 | 0.80 | HPGD (0.72) | PARP1HPGDMAPK1KDM4EHSD17B10 | |
| SCHEMBL1719968 | 0.80 | PARP1 (0.42) | PARP1HPGDCYP1A2CYP2C9MAPK1 | |
| SCHEMBL1719782 | 0.80 | PARP1 (0.42) | PARP1HPGDCYP1A2CYP2C9MAPK1 | |
| SCHEMBL1720009 | 0.79 | KDM4E (0.47) | PARP1HPGDKDM4EHSD17B10 | |
| SCHEMBL1720121 | 0.77 | PARP1 (0.53) | PARP1CYP1A2KDM4E | |
| SCHEMBL1720598 | 0.76 | PARP1 (0.49) | PARP1KDM4E | |
| SCHEMBL1720617 | 0.76 | PARP1 (0.47) | PARP1HPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4113731-A | PHOTOGRAPHIC EMULSION STABILIZERS | GRUPPO LEPETIT S.P.A. (IT) | 1978-09-12 | — | — | US | claimed |
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
| EP-0005745-B1 | PYRAZOLO (3,4-C) AND THIAZOLO (5,4-C) ISOQUINOLINES, METHODS FOR PREPARING THEM, THESE COMPOUNDS FOR USE AS ANTIINFLAMMATORY, CNS-DEPRESSANT AND ANTI-ANXIETY AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF | GRUPPO LEPETIT S.P.A. (IT) | 1982-07-14 | — | — | EP | disclosed |
| US-4232017-A | CNS DEPRESSANTS; TRANQUILIZERS | GRUPPO LEPETIT S.P.A. (IT) | 1980-11-04 | — | — | US | disclosed |
| EP-0005745-A1 | Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, CNS-depressant and anti-anxiety agents and pharmaceutical compositions thereof | GRUPPO LEPETIT S.P.A. (IT) | 1979-12-12 | — | — | EP | disclosed |
| US-4113731-A | PHOTOGRAPHIC EMULSION STABILIZERS | GRUPPO LEPETIT S.P.A. (IT) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | PARP1 1/4885HPGD 36/4885CYP1A2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.